Portfolio Holdings Detail for ISIN IE00B3VWM098

Stock Name / Fund	iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
Issuer	Blackrock
Entity holding fund	iShares VII Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300Q7FFITMZ2PFZ28
ETF Ticker	CUS1(GBX) LSE
ETF Ticker	CUSS(USD) LSE
ETF Ticker	SXRG(EUR) F
ETF Ticker	CSUSS.MI(EUR) CXE
ETF Ticker	CSUSSz(USD) CXE
ETF Ticker	CUSS.LS(USD) CXE
ETF Ticker	CSUSS(EUR) ETF Plus
ETF Ticker	CUS1.L(GBP) LSE
ETF Ticker	CUSS.L(GBP) LSE

Holdings detail for ANAB

Show aggregate ANAB holdings

News associated with ANAB

AnaptysBio (NASDAQ:ANAB) Receives “Outperform” Rating from Wedbush

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report released on Tuesday,RTT News reports. They presently have a $45.00 price target on the biotechnology company’s stock. Wedbush’s price objective points to a potential upside of 127.16% from the company’s current price. Several other […] - 2025-09-18 02:24:44

Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) Price Target at $46.13

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy […] - 2025-09-16 02:46:48

AnaptysBio, Inc. (NASDAQ:ANAB) Receives $46.13 Average Target Price from Analysts

Shares of AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) have earned an average rating of “Moderate Buy” from the ten analysts that are currently covering the company, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to […] - 2025-08-22 03:12:54

AnaptysBio (NASDAQ:ANAB) Receives Neutral Rating from UBS Group

UBS Group restated their neutral rating on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report report published on Tuesday morning, Marketbeat Ratings reports. The brokerage currently has a $20.00 price target on the biotechnology company’s stock, up from their prior price target of $18.00. A number of other research analysts have also […] - 2025-08-13 04:26:45

Zurcher Kantonalbank Zurich Cantonalbank Sells 660 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)

Zurcher Kantonalbank Zurich Cantonalbank trimmed its position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 24.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,062 shares of the biotechnology company’s stock after selling 660 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in […] - 2025-08-11 05:32:56

Federated Hermes Inc. Has $154,000 Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Federated Hermes Inc. lowered its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 8,274 shares of the biotechnology company’s stock after selling 36,910 shares during the quarter. Federated Hermes Inc.’s holdings […] - 2025-08-11 04:48:58

AnaptysBio, Inc. (NASDAQ:ANAB) Receives Average Rating of “Moderate Buy” from Analysts

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the stock, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The […] - 2025-07-30 04:24:54

Alps Advisors Inc. Lowers Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)

Alps Advisors Inc. trimmed its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 6.0% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 23,126 shares of the biotechnology company’s stock after selling 1,478 shares during the period. Alps Advisors Inc. owned […] - 2025-07-15 06:26:00

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $42.38

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-07-03 02:41:00

AnaptysBio (NASDAQ:ANAB) Upgraded at HC Wainwright

AnaptysBio (NASDAQ:ANAB – Get Free Report) was upgraded by research analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a note issued to investors on Wednesday, MarketBeat.com reports. The firm currently has a $38.00 price objective on the biotechnology company’s stock, up from their previous price objective of $22.00. HC Wainwright’s […] - 2025-06-06 02:58:51

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Acquired by Squarepoint Ops LLC

Squarepoint Ops LLC raised its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 81.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 80,870 shares of the biotechnology company’s stock after purchasing an additional 36,365 shares during the period. Squarepoint Ops LLC’s holdings in AnaptysBio were worth $1,071,000 as of its most recent filing […] - 2025-06-01 05:29:02

AnaptysBio (NASDAQ:ANAB) Earns Buy Rating from Guggenheim

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at Guggenheim in a note issued to investors on Wednesday, MarketBeat Ratings reports. They presently have a $90.00 target price on the biotechnology company’s stock, up from their previous target price of $54.00. Guggenheim’s price objective points to a […] - 2025-05-30 03:08:51

AnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Analyst Upgrade

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report)’s share price gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $52.00 to $54.00. The stock had previously closed at $20.13, but opened at $21.14. Guggenheim currently has a buy rating on the stock. AnaptysBio shares last traded at $22.10, […] - 2025-05-30 02:27:21

D. E. Shaw & Co. Inc. Reduces Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

D. E. Shaw & Co. Inc. trimmed its stake in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 12.1% during the fourth quarter, Holdings Channel reports. The fund owned 197,107 shares of the biotechnology company’s stock after selling 27,030 shares during the period. D. E. Shaw & Co. Inc.’s holdings in AnaptysBio were worth $2,610,000 as […] - 2025-05-20 04:57:05

18,954 Shares in AnaptysBio, Inc. (NASDAQ:ANAB) Bought by Graham Capital Management L.P.

Graham Capital Management L.P. bought a new position in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) in the 4th quarter, Holdings Channel.com reports. The firm bought 18,954 shares of the biotechnology company’s stock, valued at approximately $251,000. Other hedge funds also recently made changes to their positions in the company. Tower Research Capital LLC TRC increased […] - 2025-05-19 05:26:52

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.88

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the ten ratings firms that are currently covering the firm, Marketbeat reports. Four investment analysts have rated the stock with a hold recommendation, five have given a buy recommendation and one has assigned a strong buy recommendation to […] - 2025-05-14 02:34:53

Barclays PLC Boosts Stake in AnaptysBio, Inc. (NASDAQ:ANAB)

Barclays PLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 88.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,567 shares of the biotechnology company’s stock after acquiring an additional 39,267 shares during the […] - 2025-05-05 05:26:54

AnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 85.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 45,184 shares of the biotechnology company’s stock after selling 272,059 shares during the quarter. Federated […] - 2025-04-17 05:18:48

AnaptysBio, Inc. (NASDAQ:ANAB) Stock Holdings Increased by Vanguard Group Inc.

Vanguard Group Inc. lifted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 8.4% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,843,740 shares of the biotechnology company’s stock after purchasing an additional 143,584 shares during the quarter. Vanguard Group Inc. owned approximately 0.06% of AnaptysBio worth $24,411,000 as […] - 2025-04-16 04:22:49

Reviewing AnaptysBio (NASDAQ:ANAB) and Silo Pharma (NASDAQ:SILO)

AnaptysBio (NASDAQ:ANAB – Get Free Report) and Silo Pharma (NASDAQ:SILO – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, dividends, valuation, institutional ownership, profitability and risk. Risk & Volatility AnaptysBio has a beta of […] - 2025-03-25 03:56:46

Brokerages Set AnaptysBio, Inc. (NASDAQ:ANAB) Target Price at $35.11

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been given a consensus rating of “Moderate Buy” by the eleven analysts that are currently covering the company, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the […] - 2025-03-25 03:52:42

AnaptysBio (NASDAQ:ANAB) Price Target Raised to $42.00 at JPMorgan Chase & Co.

AnaptysBio (NASDAQ:ANAB – Get Free Report) had its price objective increased by JPMorgan Chase & Co. from $36.00 to $42.00 in a note issued to investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the biotechnology company’s stock. JPMorgan Chase & Co.‘s target price suggests a potential upside of 156.10% from the […] - 2025-03-07 04:10:52

AnaptysBio (NASDAQ:ANAB) Given Neutral Rating at HC Wainwright

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at HC Wainwright in a research report issued on Tuesday,Benzinga reports. They currently have a $22.00 price target on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 31.34% from the company’s previous close. Several […] - 2025-03-06 06:31:49

Analysts Set AnaptysBio, Inc. (NASDAQ:ANAB) PT at $36.20

AnaptysBio, Inc. (NASDAQ:ANAB – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the eleven research firms that are currently covering the firm, Marketbeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation […] - 2025-02-28 04:26:55

Jennison Associates LLC Boosts Stock Position in AnaptysBio, Inc. (NASDAQ:ANAB)

Jennison Associates LLC boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) by 1.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 269,131 shares of the biotechnology company’s stock after acquiring an additional 4,242 shares during the […] - 2025-02-07 07:55:30

Wedbush Predicts AnaptysBio’s Q1 Earnings (NASDAQ:ANAB)

AnaptysBio, Inc. (NASDAQ:ANAB – Free Report) – Equities research analysts at Wedbush lifted their Q1 2025 earnings estimates for AnaptysBio in a research note issued on Monday, February 3rd. Wedbush analyst D. Nierengarten now expects that the biotechnology company will earn ($0.44) per share for the quarter, up from their previous estimate of ($0.96). Wedbush […] - 2025-02-06 04:36:55

Wolfe Research Initiates Coverage on AnaptysBio (NASDAQ:ANAB)

Wolfe Research assumed coverage on shares of AnaptysBio (NASDAQ:ANAB – Free Report) in a research report sent to investors on Tuesday, Marketbeat Ratings reports. The brokerage issued an outperform rating and a $25.00 target price on the biotechnology company’s stock. Several other research firms also recently commented on ANAB. Guggenheim cut their target price on […] - 2025-02-05 07:10:52

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc ANAB holdings

Date	Number of ANAB Shares Held	Base Market Value of ANAB Shares	Local Market Value of ANAB Shares	Change in ANAB Shares Held	Change in ANAB Base Value	Current Price per ANAB Share Held	Previous Price per ANAB Share Held
2025-09-26 (Friday)	6,131	USD 144,569	USD 144,569
2025-09-25 (Thursday)	6,131	USD 135,127	USD 135,127	0	USD -613	USD 22.04	USD 22.1399
2025-09-24 (Wednesday)	6,131	USD 135,740	USD 135,740
2025-09-17 (Wednesday)	6,093	USD 120,702	USD 120,702	0	USD 2,498	USD 19.8099	USD 19.4
2025-09-16 (Tuesday)	6,093	USD 118,204	USD 118,204
2025-09-12 (Friday)	6,055	USD 141,687	USD 141,687
2025-09-11 (Thursday)	6,055	USD 140,476	USD 140,476	76	USD 7,802	USD 23.2	USD 22.19

Share Trades of ANAB by Blackrock for IE00B3VWM098

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-09-11	BUY	76			23.200*		21.03
2025-08-21	SELL	-3			20.360*		21.03 Profit of 63 on sale
2025-07-31	BUY	9			24.550*		21.02
2025-06-30	SELL	-6			22.200*		20.47 Profit of 123 on sale
2025-06-25	SELL	-3			23.240*		20.42 Profit of 61 on sale
2025-06-20	SELL	-6			23.170*		20.36 Profit of 122 on sale
2025-05-30	SELL	-4,505			22.230*		20.03 Profit of 90,256 on sale
2025-05-23	BUY	18			20.440*		20.00
2025-05-19	SELL	-18			20.470*		19.97 Profit of 359 on sale
2025-05-15	SELL	-54			20.400*		19.97 Profit of 1,078 on sale
2025-05-12	SELL	-18			20.030*		19.97 Profit of 359 on sale
2025-05-09	SELL	-18			19.590*		19.97 Profit of 359 on sale
2025-04-30	SELL	-18			22.220*		19.92 Profit of 358 on sale
2025-04-24	SELL	-36			20.610*		19.87 Profit of 715 on sale
2025-04-17	SELL	-18			20.550*		19.83 Profit of 357 on sale
2025-04-15	SELL	-54			18.100*		19.85 Profit of 1,072 on sale
2025-04-14	SELL	-54			17.860*		19.88 Profit of 1,073 on sale
2025-04-09	SELL	-72			16.900*		19.98 Profit of 1,439 on sale
2025-04-07	SELL	-126			17.780*		20.04 Profit of 2,525 on sale
2025-04-04	SELL	-180			18.510*		20.06 Profit of 3,611 on sale
2025-03-31	BUY	18			18.590*		20.11
2025-03-19	SELL	-36			16.440*		20.34 Profit of 732 on sale
2025-03-14	SELL	-108			16.730*		20.50 Profit of 2,214 on sale
2025-03-13	SELL	-36			16.840*		20.56 Profit of 740 on sale
2025-03-12	SELL	-612			17.710*		20.60 Profit of 12,606 on sale
2025-03-07	SELL	-36			16.340*		20.77 Profit of 748 on sale
2025-03-06	SELL	-54			16.400*		20.83 Profit of 1,125 on sale
2025-03-03	SELL	-18			14.640*		21.09 Profit of 380 on sale
2025-02-28	SELL	-29,302			16.820*		21.16 Profit of 620,047 on sale
2025-02-26	SELL	-95			17.000*		21.31 Profit of 2,025 on sale
2025-02-25	SELL	-288			17.190*		21.38 Profit of 6,158 on sale
2025-02-18	BUY	475			19.780*		21.63
2025-02-13	BUY	190			19.290*		21.69
2025-02-11	BUY	285			12.375*		22.00
2025-02-06	BUY	855			16.080*		22.49
2025-01-27	BUY	95			17.460*		23.64
2024-12-30	BUY	475			13.220*		24.69
2024-12-06	BUY	380			24.810*		24.80
2024-12-05	BUY	95			23.660*		24.84
2024-12-04	BUY	475			24.080*		24.86
2024-11-29	BUY	475			24.960*		24.99
2024-11-27	BUY	380			25.120*		24.98
2024-11-26	BUY	95			25.250*		24.97
2024-11-25	BUY	9,821			24.100*		25.01
2024-11-21	BUY	325			21.170*		25.36
2024-11-20	BUY	195			20.310*		25.64
2024-11-18	BUY	780			18.880*		26.41
2024-11-12	BUY	520			21.500*		26.74
2024-11-08	BUY	325			21.310*		27.13
2024-11-07	BUY	975			21.490*		27.56
2024-11-06	BUY	130			22.210*		28.01
2024-10-31	BUY	65			21.630*		31.62

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of ANAB

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer